A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1
- Study design
- NON RANDOMIZED · PARALLEL · BASIC SCIENCE · NONE
- Evidence population
- Human clinical study registration
- Participants
- 50
- Population
- ALL · 55 Years to 90 Years
- Duration
- 2013-05-01 to 2014-11-01
- Intervention
- CLG561
- Comparator
- Not reported
- Outcomes measured
- Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) by Visit - Study Eye — Baseline, Day 2, Day 4, Day 15,…; Mean Intra-Ocular Pressure (IOP) by Visit - Study Eye — Baseline, Day 1, Day 2, Day 4, Day 15, Day 29, Day 57, Day 85; Number of Subjects With Change From Normal to Abnormal in Fundus Examination at Any Post-Therapy Visit as Compared to B…; Number of Subjects With a Change From Normal to Abnormal in Ocular Signs at Any Post-Therapy Visit as Compared to Basel…; Area Under the Serum Concentration-time Curve (AUC) From Time Zero to All [AUC(0-all)] — Day 1 pre-injection, 2h, 6h, D…; Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration [AUC(0-…; Time to Reach the Maximum Serum Concentration After Drug Administration (Tmax) — Day 1 pre-injection, 2h, 6h, Day 2, Da…; Dose Normalized Observed Maximum Serum Concentration Following Drug Administration (Cmax/D) — Day 1 pre-injection, 2h,…; Dose-normalized Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Conce…; Area Under the Serum Concentration-time Curve From Time Zero to Time "t" Where t is a Defined Time Point After Administ…; Terminal Elimination Half-life (T½) — Day 1 pre-injection, 2h, 6h, Day 2, Day 4, Day 6, Day 8, Day 11, Day 15, Day 29,…; The Apparent Volume of Distribution During the Terminal Elimination Phase Following Extravascular Administration (Vz/F)…; Apparent Systemic (or Total Body) Clearance From Serum Following Extravascular Administration (CL/F) — Day 1 pre-inject…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.
Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.